Q Qi1, Y Wu, H Li, R J F Loos, F B Hu, L Sun, L Lu, A Pan, C Liu, H Wu, L Chen, Z Yu, X Lin. 1. Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
Abstract
AIMS/HYPOTHESIS: The GCKR rs780094 and GCK rs1799884 polymorphisms have been reported to be associated with dyslipidaemia and type 2 diabetes in white Europeans. The aim of this study was to replicate these associations in Han Chinese individuals and to identify the potential mechanisms underlying these associations. METHODS: The single nucleotide polymorphisms rs780094 and rs1799884 were genotyped in a population-based sample of Han Chinese individuals (n = 3,210) and tested for association with risk of type 2 diabetes and related phenotypes. RESULTS: The GCKR rs780094 A allele was marginally associated with reduced risk of type 2 diabetes (OR 0.85, 95% CI 0.73-1.00, p value under an additive model [p((add))] = 0.05) and significantly associated with reduced risk of impaired fasting glucose (IFG) or type 2 diabetes (OR 0.86, 95% CI 0.77-0.96, p([add]) = 0.0032). It was also significantly associated with decreased fasting glucose and increased HOMA of beta cell function (HOMA-B) and fasting triacylglycerol levels (p([add]) = 0.0169-5.3 x 10(-6)), but not with HOMA of insulin sensitivity (HOMA-S). The associations with type 2 diabetes and IFG remained significant after adjustment for BMI, while adjustment for HOMA-B abolished the associations. The GCKR rs780094 was also associated with obesity and BMI, independently of its association with type 2 diabetes. The GCK rs1799884 A allele was significantly associated with decreased HOMA-B (p([add]) = 0.0005), but not with type 2 diabetes or IFG. Individuals with increasing numbers of risk alleles for both variants had significantly lower HOMA-B (p([add]) = 5.8 x 10(-5)) in the combined analysis. CONCLUSIONS/ INTERPRETATION: Consistent with observations in white Europeans, the GCKR rs780094 polymorphism contributes to the risk of type 2 diabetes and dyslipidaemia in Han Chinese individuals. In addition, we showed that the effect on type 2 diabetes is probably mediated through impaired beta cell function rather than through obesity.
AIMS/HYPOTHESIS: The GCKRrs780094 and GCKrs1799884 polymorphisms have been reported to be associated with dyslipidaemia and type 2 diabetes in white Europeans. The aim of this study was to replicate these associations in Han Chinese individuals and to identify the potential mechanisms underlying these associations. METHODS: The single nucleotide polymorphisms rs780094 and rs1799884 were genotyped in a population-based sample of Han Chinese individuals (n = 3,210) and tested for association with risk of type 2 diabetes and related phenotypes. RESULTS: The GCKRrs780094 A allele was marginally associated with reduced risk of type 2 diabetes (OR 0.85, 95% CI 0.73-1.00, p value under an additive model [p((add))] = 0.05) and significantly associated with reduced risk of impaired fasting glucose (IFG) or type 2 diabetes (OR 0.86, 95% CI 0.77-0.96, p([add]) = 0.0032). It was also significantly associated with decreased fasting glucose and increased HOMA of beta cell function (HOMA-B) and fasting triacylglycerol levels (p([add]) = 0.0169-5.3 x 10(-6)), but not with HOMA of insulin sensitivity (HOMA-S). The associations with type 2 diabetes and IFG remained significant after adjustment for BMI, while adjustment for HOMA-B abolished the associations. The GCKRrs780094 was also associated with obesity and BMI, independently of its association with type 2 diabetes. The GCKrs1799884 A allele was significantly associated with decreased HOMA-B (p([add]) = 0.0005), but not with type 2 diabetes or IFG. Individuals with increasing numbers of risk alleles for both variants had significantly lower HOMA-B (p([add]) = 5.8 x 10(-5)) in the combined analysis. CONCLUSIONS/ INTERPRETATION: Consistent with observations in white Europeans, the GCKRrs780094 polymorphism contributes to the risk of type 2 diabetes and dyslipidaemia in Han Chinese individuals. In addition, we showed that the effect on type 2 diabetes is probably mediated through impaired beta cell function rather than through obesity.
Authors: E D Slosberg; U J Desai; B Fanelli; I St Denny; S Connelly; M Kaleko; B R Boettcher; S L Caplan Journal: Diabetes Date: 2001-08 Impact factor: 9.461
Authors: Anna L Gloyn; Kees Noordam; Michèl A A P Willemsen; Sian Ellard; Wayne W K Lam; Ian W Campbell; Paula Midgley; Chyio Shiota; Carol Buettger; Mark A Magnuson; Franz M Matschinsky; Andrew T Hattersley Journal: Diabetes Date: 2003-09 Impact factor: 9.461
Authors: Juan M Gómez-Zumaquero; G Rojo-Martínez; E García-Escobar; Gracia M Martín-Nuñez; J Haro; I Esteva; M Ruiz de Adana; Antonio L Cuesta; G Olveira; S Morcillo; F Soriguer Journal: Obesity (Silver Spring) Date: 2008-05-15 Impact factor: 5.002
Authors: Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Henrik B T Christesen; Bendt B Jacobsen; Stella Odili; Carol Buettger; Antonio Cuesta-Munoz; Torben Hansen; Klaus Brusgaard; Ornella Massa; Mark A Magnuson; Chiyo Shiota; Franz M Matschinsky; Fabrizio Barbetti Journal: Diabetes Date: 2002-04 Impact factor: 9.461
Authors: Stéphane Cauchi; Kevin T Nead; Hélène Choquet; Fritz Horber; Natascha Potoczna; Beverley Balkau; Michel Marre; Guillaume Charpentier; Philippe Froguel; David Meyre Journal: BMC Med Genet Date: 2008-05-22 Impact factor: 2.103
Authors: F Takeuchi; T Katsuya; S Chakrewarthy; K Yamamoto; A Fujioka; M Serizawa; T Fujisawa; E Nakashima; K Ohnaka; H Ikegami; T Sugiyama; T Nabika; A Kasturiratne; S Yamaguchi; S Kono; R Takayanagi; Y Yamori; S Kobayashi; T Ogihara; A de Silva; R Wickremasinghe; N Kato Journal: Diabetologia Date: 2009-11-25 Impact factor: 10.122
Authors: Min Xu; Xiaofei Lv; Lan Xie; Xiaolin Huang; Ya Huang; Ying Chen; Kui Peng; Po Wang; Weiqing Wang; Lu Qi; Yufang Bi; Yimin Sun; Guang Ning Journal: Diabetologia Date: 2015-10-29 Impact factor: 10.122
Authors: Ferenc Hadarits; Péter Kisfali; Márton Mohás; Anita Maász; Balázs Duga; Ingrid Janicsek; István Wittmann; Béla Melegh Journal: Mol Biol Rep Date: 2011-06-04 Impact factor: 2.316
Authors: Claudia Ha Ting Tam; Janice Sin Ka Ho; Ying Wang; Heung Man Lee; Vincent Kwok Lim Lam; Soren Germer; Mitchell Martin; Wing Yee So; Ronald Ching Wan Ma; Juliana Chung Ngor Chan; Maggie Chor Yin Ng Journal: PLoS One Date: 2010-07-08 Impact factor: 3.240
Authors: Mark Bi; Wen Hong Linda Kao; Eric Boerwinkle; Ron C Hoogeveen; Laura J Rasmussen-Torvik; Brad C Astor; Kari E North; Josef Coresh; Anna Köttgen Journal: PLoS One Date: 2010-07-22 Impact factor: 3.240
Authors: Raquel Villegas; Ryan Delahanty; Scott Williams; Honglan Li; Richard O'Brian; Jiajun Shi; Qiuyin Cai; Yong-Bing Xiang; Xiao Ou Shu Journal: Ann Hum Genet Date: 2015-08-07 Impact factor: 1.670